Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
Yahoo Finance · May 14, 2026 · Chemomab Therapeutics Ltd DRC (CMMB)
—New Clinical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC Patients with Co-Existing IBD— —Company Continues to Advance Multiple Partnering Options for Nebokitug— TEL AVIV, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics
Not investment advice. Cached headline, not a full reprint.